SCHEMBL29997995

SCHEMBL29997995

CC(C)(C)OC(=O)N1CC[C@@H](OC(=O)c2ccccc2)[C@@H]1Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 1/20 0.46
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
NR1H2 P55055 2/20 0.42
NR1H3 Q13133 2/20 0.42
GPR119 Q8TDV5 2/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
STS P08842 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
RAB9A P51151 1/20 0.41
FOLH1 Q04609 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29997845 0.93 KLK7 (0.48) KLK7KDM4EPKMNR1H2NR1H3
SCHEMBL7297892 0.87 KLK7 (0.47) KLK7KDM4EPKMGPR119JAK2
SCHEMBL29997519 0.86 KLK7 (0.46) KLK7KDM4EPKMNR1H2NR1H3
SCHEMBL13625747 0.85 KDM4E (0.42) KLK7KDM4EPKMGPR119MEN1
SCHEMBL145604 0.85 KDM4E (0.42) KLK7KDM4EPKMGPR119STS
SCHEMBL23458995 0.85 RAB9A (0.46) MEN1KMT2ARAB9AFOLH1CHRM2
SCHEMBL23458993 0.85 RAB9A (0.46) MEN1KMT2ARAB9AFOLH1CHRM2
SCHEMBL29998091 0.84 SLC6A2 (0.47) KLK7KMT2ARAB9A
SCHEMBL25698124 0.84 SLC6A2 (0.47) KLK7KMT2ARAB9A
SCHEMBL30718564 0.82 MEN1 (0.45) KLK7KDM4EPKMGPR119MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4069366-B1 ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION INC (US) 2025-03-19 EP disclosed
US-11685734-B2 ATM kinase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2023-06-27 US disclosed
EP-4069366-A1 ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation, Inc. (US) 2022-10-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685734-B2 ATM kinase inhibitors and compositions and methods of use thereof ATM, CHEK2, CHEK1 KLK7 2147/4885KDM4E 1914/4885PKM 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.